These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19227191)

  • 1. [May-Hegglin anomaly: past and present--novel diagnostic test and new concept of the disease].
    Kunishima S
    Rinsho Byori; 2009 Jan; 57(1):54-9. PubMed ID: 19227191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
    Kunishima S
    Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [May-Hegglin anomaly--from genome research to clinical laboratory].
    Kunishima S
    Rinsho Byori; 2003 Sep; 51(9):898-904. PubMed ID: 14560660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions.
    Kunishima S; Matsushita T; Kojima T; Amemiya N; Choi YM; Hosaka N; Inoue M; Jung Y; Mamiya S; Matsumoto K; Miyajima Y; Zhang G; Ruan C; Saito K; Song KS; Yoon HJ; Kamiya T; Saito H
    J Hum Genet; 2001; 46(12):722-9. PubMed ID: 11776386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestation and molecular genetic characterization of MYH9 disorders.
    Provaznikova D; Geierova V; Kumstyrova T; Kotlin R; Mikulenkova D; Zurkova K; Matoska V; Hrachovinova I; Rittich S
    Platelets; 2009 Aug; 20(5):289-96. PubMed ID: 19557653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution melting analysis for detection of MYH9 mutations.
    Provaznikova D; Kumstyrova T; Kotlin R; Salaj P; Matoska V; Hrachovinova I; Rittich S
    Platelets; 2008 Sep; 19(6):471-5. PubMed ID: 18925516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
    Kunishima S; Yoshinari M; Nishio H; Ida K; Miura T; Matsushita T; Hamaguchi M; Saito H
    Eur J Haematol; 2007 Mar; 78(3):220-6. PubMed ID: 17241369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Usefulness of immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A for diagnosing in two sisters with May-Hegglin anomaly].
    Kimura N; Matsumoto M; Matsumoto K; Asai N; Kunishima S
    Rinsho Ketsueki; 2008 Dec; 49(12):1614-8. PubMed ID: 19110523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the understanding of MYH9 disorders.
    Kunishima S; Saito H
    Curr Opin Hematol; 2010 Sep; 17(5):405-10. PubMed ID: 20601875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders.
    Kunishima S; Hamaguchi M; Saito H
    Blood; 2008 Mar; 111(6):3015-23. PubMed ID: 18192507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYH9-related platelet disorders.
    Althaus K; Greinacher A
    Semin Thromb Hemost; 2009 Mar; 35(2):189-203. PubMed ID: 19408192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).
    Selleng K; Lubenow LE; Greinacher A; Warkentin TE
    Eur J Haematol; 2007 Sep; 79(3):263-8. PubMed ID: 17655694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.
    Seri M; Cusano R; Gangarossa S; Caridi G; Bordo D; Lo Nigro C; Ghiggeri GM; Ravazzolo R; Savino M; Del Vecchio M; d'Apolito M; Iolascon A; Zelante LL; Savoia A; Balduini CL; Noris P; Magrini U; Belletti S; Heath KE; Babcock M; Glucksman MJ; Aliprandis E; Bizzaro N; Desnick RJ; Martignetti JA
    Nat Genet; 2000 Sep; 26(1):103-5. PubMed ID: 10973259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunofluorescence localization of inclusion and identification of nonmuscle myosin heavy chain IIA in neutrophils of May-Hegglin anomaly patients].
    Yi Y; Zhang GS
    Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1313-6. PubMed ID: 12930685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.
    Sekine T; Konno M; Sasaki S; Moritani S; Miura T; Wong WS; Nishio H; Nishiguchi T; Ohuchi MY; Tsuchiya S; Matsuyama T; Kanegane H; Ida K; Miura K; Harita Y; Hattori M; Horita S; Igarashi T; Saito H; Kunishima S
    Kidney Int; 2010 Jul; 78(2):207-14. PubMed ID: 20200500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of clinical manifestations, mutant gene and encoded protein in two Chinese MYH9-related disease families.
    Yi Y; Sen Zhang G; Xu M; San Ling Z; Ru Shao X; Zeng Li J; Ma J
    Clin Chim Acta; 2006 Nov; 373(1-2):49-54. PubMed ID: 16806139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders.
    Pecci A; Noris P; Invernizzi R; Savoia A; Seri M; Ghiggeri GM; Sartore S; Gangarossa S; Bizzaro N; Balduini CL
    Br J Haematol; 2002 Apr; 117(1):164-7. PubMed ID: 11918549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the first in cis mutations in MYH9 disorder.
    Miyajima Y; Kunishima S
    Eur J Haematol; 2009 Apr; 82(4):288-91. PubMed ID: 19191864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome.
    Deutsch S; Rideau A; Bochaton-Piallat ML; Merla G; Geinoz A; Gabbiani G; Schwede T; Matthes T; Antonarakis SE; Beris P
    Blood; 2003 Jul; 102(2):529-34. PubMed ID: 12649151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.